An evaluation of estramustine, docetaxel and zoledronate [zoledronic acid] in patients with hormone-refractory adenocarcinoma of the prostate
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2019
At a glance
- Drugs Zoledronic acid (Primary) ; Docetaxel; Estramustine
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 21 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Nov 2005 New trial record.